中药糖类上市药物研究进展  

Research Progress in Marketed Carbohydrate Drugs from Traditional Chinese Medicine

作　　者：王登辉 李欣怡 程国良 叶楚璇 李冰 关永霞 王义忠 严诗楷[3] 肖雪 WANG Deng-hui;LI Xin-yi;CHENG Guo-liang;YE Chu-xuan;LI Bing;GUAN Yong-xia;WANG Yi-zhong;YAN Shi-kai;XIAO Xue(Institute of Traditional Chinese Medicine,Guangdong Pharmaceutical University,Guangzhou 510006,China;Lunan Pharmaceutical Group Co.,Ltd.,Linyi 276000,China;School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China)

机构地区：[1]广东药科大学中医药研究院,广东广州510006 [2]鲁南制药集团股份有限公司,山东临沂276000 [3]上海交通大学药学院,上海200240

出　　处：《化学试剂》2023年第6期26-34,共9页Chemical Reagents

基　　金：山东省重大科技创新工程项目(2021CXGC010508);广州市科技计划项目珠江科技新星专项项目(201610010113);国家药品监督管理局快速检验技术重点实验室开放课题项目(KF2022002,KF2022006)。

摘　　要：中药糖类上市药物常用于恶性肿瘤、神经系统、泌尿系统、免疫系统等疾病的治疗或辅助治疗。研究表明中药糖类上市药物主要通过调节细胞因子、免疫系统、肠道菌群等途径达到抗肿瘤、抗病毒、抗炎、调节血糖、增强免疫等作用。现阶段糖类药物的研究越来越多,通过归纳梳理中药糖类上市药物在临床应用、基础研究及质量控制等方面的研究现状,为中药糖类上市药物的研究与开发利用提供了参考。Carbohydrate drugs from traditional Chinese medicine(TCM carbohydrate drugs) are often used in the treatment or adjuvant treatment of malignant tumors,nervous,urinary,and immune system related diseases.Studies have shown that TCM carbohydrate drugs can achieve anti-tumor,anti-virus,anti-inflammatory,blood sugar regulation and immune enhancement through regulating cytokines,immune system,intestinal flora and other pathways.At present,there are increasing interests in carbohydrate drugs research.In this review,the research status of TCM carbohydrate marketed drugs in clinical application basic research and quality control was summarized,providing a reference for the research,development and utilization of carbohydrate drugs.

关 键 词：糖类 中药 临床应用 基础研究 质量控制 

分 类 号：R932[医药卫生—生药学]